How does EVQLV’s technology work?

Jun 1, 2020 | Blog | 0 comments

Daniel Gigante

This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video).

Transcription:

We use nearly a hundred billion data points across a wide range of biological data. That includes gene sequences, biological structures, biophysical properties and more. And we integrate all that data and then apply our evolutionary algorithms and computational tests. This all gives our artificial intelligence engine the ability to make statistically informed decisions.

To be clear, this process is not about replacing the work of scientists in the lab. Instead, it’s about accelerating and augmenting the decision-making being made by life scientists as they work on drugs for the coronavirus.

We’re driven, at our company, to use computational technology to support each key member in the drug discovery and development process, in order to prevent failure in the lab, in animal tests, or in clinical trials.

Today, our technology works by taking an existing antibody sequence. For example, an antibody that targets the spike of the coronavirus that may have come from an animal or a patient that recovered from the coronavirus. We then apply our proprietary evolutionary algorithms to generate evolutionary mutated daughters of those antibodies. By taking those antibodies that we know target the coronavirus and applying our algorithms, we can generate variants that could be used in larger segments of the population.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

EVQLV Applies Proprietary AI Technology in Collaboration with Twist Bioscience to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

EVQLV’s Evolutionary Algorithm Explained

Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.

Andrew Satz on the Talent Finders Podcast

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.

Pin It on Pinterest